Health Care(IN20339.HK)

The Nasdaq Golden Dragon China Index preliminarily closed down 0.6%. Among popular Chinese concept stocks, Tencent Music fell 4.9%, Kingsoft Cloud fell 4.6%, and Zai Lab fell 4.1%. In ETFs, KWEB fell 1.1%, CQQQ rose 0.22%, and ASHR rose 0.8%

Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors

Ascentage Pharma Group International has unveiled its 2026 global innovation strategy, focusing on expanding clinical development and product commercialization in hematologic malignancies and solid tumors. The plan includes advancing its innovative therapy pipeline, progressing multiple global Phase III trials, and developing APG-3288, a next-generation BTK degrader. The company aims to meet unmet clinical needs and enhance its global portfolio of products and clinical programs.

CSPC PHARMA's subsidiary, CSPC Innovation, reported a loss of at least 170 million RMB last year

CSPC PHARMA's subsidiary, CSPC Innovation, issued a profit warning, expecting a loss of between 170 million and 250 million RMB for the fiscal year 2025, compared to a profit of 53.73 million RMB in the previous year. The reasons for the loss include an increase in R&D expenses to approximately 1 billion RMB, the acquisition of a minority stake in the controlling subsidiary, Jushi Biotech, leading to a greater impact on net profit, and a decrease in the gross profit margin of the functional raw materials business

Frontage Holdings Opens Fully Operational GMP Facility with Advanced Manufacturing Capabilities

Frontage Holdings Corporation has launched a new GMP facility, operational since October 2025, enhancing its pharmaceutical development and manufacturing capabilities. The facility includes advanced equipment for aseptic filling, tablet pressing, and more, supporting clinical and small-scale commercial production of various dosage forms. This expansion aims to provide efficient manufacturing solutions for small and mid-sized pharmaceutical companies.

China Health Technology Group Appoints Cao Xiying as Executive Director

China Health Technology Group Holding Co. Ltd. has appointed Ms. Cao Xiying as an executive director, effective January 15, 2026. The board now includes Ms. Bu Xue and Ms. Cao Xiying as executive directors, along with Mr. Chau Wing Nam, Ms. Liu Shuhua, and Mr. Li Liangjie as independent non-executive directors. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.